Journal
AMERICAN SURGEON
Volume 88, Issue 3, Pages 471-479Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/00031348211047205
Keywords
breast; surgical oncology; neoadjuvant endocrine therapy; hormone receptor positive breast cancer; healthcare resource limitation
Categories
Ask authors/readers for more resources
The study compared treatment methods and outcomes of patients diagnosed with HR+/HER2- breast cancer in 2019 and 2020, finding that more patients in 2020 utilized neoadjuvant endocrine therapy as bridging therapy. The impact on clinical and pathologic staging was similar across different treatment approaches, but neoadjuvant endocrine therapy was shown to optimize healthcare utilization.
Background The COVID-19 pandemic has required new treatment paradigms to limit exposures and optimize hospital resources, including the use of neoadjuvant endocrine therapy (NAET) as bridging therapy for HR+/HER2-invasive tumors and DCIS. While this approach has been used in locally advanced disease, it is unclear how it may affect outcomes in resectable HR+/HER2- tumors. Methods Women >= 18 years diagnosed with in situ (Tis) or non-metastatic HR+/HER2- breast cancer from March-May 2019 and 2020 were included. Fisher's exact test and two-sample t test were used to compare baseline characteristics and surgical outcomes between strata. Sub-analysis was performed between patients who received primary surgery vs a bridging NAET approach. Results Despite similar clinical characteristics, patients in 2019 were more likely to have a surgery-first approach (75% vs 42%, P-value = .0007), receive surgery sooner (22 vs 29 days, P-value < .001), and within 60 days from diagnosis date (100% vs 85%, P-value = .0301). Neoadjuvant endocrine therapy was a more prevalent approach in 2020 (48% vs 7%, P-value < .0001). Rates of clinical to pathologic up-staging remained consistent across primary surgery vs bridging NAET subgroups (P-value = .9253). Discussion Pandemic-driven treatment protocols provide a unique opportunity to assess the utility of bridging endocrine therapy for resectable HR+/HER2- tumors. Differences in clinical and pathologic staging were similar across groups and did not appear to be affected by receipt of NAET. Our limited cohort demonstrates this strategic therapeutic avenue can optimize health care utilization and may be a reasonable approach when delaying surgery is preferred.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available